Mutated cytosine deaminases with improved editing accuracy
Through the variable-form base editor (tBE) system, combined with the specific mA3CDA1 catalytic domain mutation, the problem of off-target editing and editing window expansion in the existing technology is solved, efficient and accurate C-to-T editing is achieved, and the editing position is significantly improved point accuracy.
Patent Information
- Application Number
- CN202380033191.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-17
- Filing Date
- 2023-02-17
- Publication Date
- 2024-11-22
AI Technical Summary
Existing genome editing tools such as CRISPR/Cas9 systems and base editors are often accompanied by side effects and unnecessary base changes related to off-target editing, resulting in an expansion of the editing window and a decrease in the accuracy of the editing site.
A variable form base editor (tBE) system was developed to combine conventional cytosine deaminases with cleavable deaminase inhibitors to activate the catalytic domain only at the target site for precise C-to-T substitutions, By designing specific mA3CDA1 catalytic domain mutations such as Y35D and K40H-W102Y, off-target mutations are reduced and editing windows are narrowed.
It achieves efficient and specific editing of cytosine in the target region without off-target mutations, significantly improving the accuracy and editing efficiency of the editing site and reducing unnecessary base changes.
Smart Images

Figure BDA0005075997120000011 
Figure BDA0005075997120000021 
Figure BDA0005075997120000081
Abstract
Description
Background Art
[0001] The combination of CRISPR-Cas9 and cytosine deaminase has generated a cytosine base editor (CBE) for programmable cytosine to thymine (C to T) substitution, which has been successfully applied to achieve efficient editing in multiple species and has great potential in clinical applications. Since the base editing process does not rely on the generation of DNA double-strand breaks (DSBs), unwanted nucleotide insertions / deletions (indels) or DNA damage response (DDR) can be largely avoided.
[0002] The variant base editor (tBE) system contains a cytosine deaminase inhibitor (dCDI) domain and a split TEV protease (see, e.g., WO2020156575). Therefore, tBE is able to remain inactive at off-target sites due to its cleavable dCDI domain fusion, and eliminates unexpected off-target mutations. Only when bound to the targeted site is tBE converted to remove the dCDI domain and catalyze targeted deamination for precise editing. Specifically, tBE uses sgRNA (usually 20nt) to bind to the target genomic site, and uses auxiliary sgRNA (hsgRNA, usually 10nt to 20nt) to bind to the adjacent region (preferably upstream of the target genomic site). The combination of the two gRNAs can guide the correct assembly of the tBE system components at the target genomic site for base editing. tBE can specifically edit cytosine in the target region without observable off-target mutations. Summary of the invention
[0003] In some embodiments, the present disclosure provides mutated cytosine deaminases and related molecules for base editing, which have reduced off-target mutations or no off-target mutations and have improved editing site accuracy. The mutated catalytic domain (mA3CDA1) of mouse APOBEC3 protein contains one or more mutations that help to narrow the editing window while maintaining high editing efficiency. Exemplary mutations include Y35D and K40H-W102Y. Also provided are improved primer editing systems and methods using these mutated cytosine deaminases.
[0004] According to one embodiment of the present disclosure, a protein is provided, which comprises the catalytic domain of a mutated mouse APOBEC3 protein, wherein the catalytic domain has at least 85% sequence identity with amino acid residues 35-141 of SEQ ID NO:1, and comprises a substitution at a residue selected from the group consisting of Y35, K37, R39, K40, N66, W102, Y132 and a combination thereof relative to SEQ ID NO:1.
[0005] In some embodiments, the substitution is selected from the group consisting of:
[0006] In some embodiments, the catalytic domain retains the amino acids of SEQ ID NO: 1 at residues H71 and E73. In some embodiments, the catalytic domain retains the amino acids of SEQ ID NO: 1 at residues D41, F43, F64, A72, P104, C105, and C108. In some embodiments, the substitution is selected from the group consisting of Y35D, Y35E, K37D, R39A, K40A, K40H, N66A, N66G, N66Q, W102Y, W102F, Y132F, and combinations thereof.
[0007] In some embodiments, the substitution is Y35D or Y35E. In some embodiments, the catalytic domain comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, the substitution is K40H and W102Y. In some embodiments, the catalytic domain comprises the amino acid sequence of SEQ ID NO: 5.
[0008] Also provided is a fusion protein comprising a first fragment and a second fragment, the first fragment comprising a protein of the present disclosure, the second fragment comprising a nucleobase deaminase inhibitor. In some embodiments, the fusion protein further comprises a protease cleavage site between the first fragment and the second fragment. In some embodiments, the nucleobase deaminase inhibitor is an inhibitory domain of a nucleobase deaminase.
[0009] In some embodiments, the nucleobase deaminase inhibitor comprises the amino acid sequence of SEQ ID NO:7, 8, or 9, or amino acid residues 128-223 of SEQ ID NO:7.
[0010] In some embodiments, a dual guide RNA system is also provided, comprising: a target single guide RNA comprising a first spacer having sequence complementarity with a target nucleic acid sequence adjacent to a first PAM site, an auxiliary single guide RNA comprising a second spacer having sequence complementarity with a second nucleic acid sequence adjacent to a second PAM site, a clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) protein, and a protein or fusion protein of the present disclosure.
[0011] In some embodiments, the second PAM site is 34 to 91 bases away from the first PAM site.
[0012] Yet another embodiment provides a method for introducing a C to T substitution at a cytosine of a target nucleic acid, the method comprising contacting the target nucleic acid with a CRISPR-associated (Cas) protein, a protein or fusion protein of the present disclosure, a single guide RNA (sgRNA), and a helper single guide RNA (hsgRNA), wherein the sgRNA and the hsgRNA are capable of hybridizing to the target nucleic acid.
[0013] In some embodiments, the cytosine is located between the 4th and 8th nucleotides of the 3' end of the protospacer adjacent motif (PAM) sequence on the target nucleic acid sequence. In some embodiments, the cytosine is located between the 6th and 8th nucleotides of the 3' end of the protospacer adjacent motif (PAM) sequence on the target nucleic acid sequence.
[0014] In another embodiment, a method for introducing a C to T substitution at a cytosine in a target nucleic acid is provided, the method comprising contacting the target nucleic acid with a CRISPR-associated (Cas) protein, a fusion protein of the present disclosure, a single guide RNA (sgRNA), and a helper single guide RNA (hsgRNA), wherein the sgRNA and the hsgRNA are capable of hybridizing to the target nucleic acid, wherein the cytosine is located between nucleotides 6 and 8 of the 3' end of a protospacer adjacent motif (PAM) sequence on the target nucleic acid sequence, and wherein the catalytic domain comprises the amino acid sequence of SEQ ID NO: 3.
[0015] Also provided is a method for introducing a C to T substitution at a cytosine in a target nucleic acid, the method comprising contacting the target nucleic acid with a CRISPR-associated (Cas) protein, a fusion protein of the present disclosure, a single guide RNA (sgRNA), and a helper single guide RNA (hsgRNA), wherein the sgRNA and the hsgRNA are capable of hybridizing with the target nucleic acid, wherein the cytosine is located between the 4th and 8th nucleotides at the 3' end of a protospacer adjacent motif (PAM) sequence on the target nucleic acid sequence, and wherein the catalytic domain comprises the amino acid sequence of SEQ ID NO: 5. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The editing efficiency induced by sgRNA-hVEGFA1 / hsgRNA-hVEGFA1 and tBE variants containing single AA changes is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA-hVEGFA1 / hsgRNA-hVEGFA1 with tBE or tBE variants containing single AA changes as indicated. (B): Editing efficiency induced by the original tBE and tBE variants in (A) with sgRNA-hVEGFA1 / hsgRNA-hVEGFA1.
[0017] Figure 2The editing efficiency induced by sgRNA-hVEGFA1 / hsgRNA-hVEGFA1 and tBE variants containing double AA changes is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA-hVEGFA1 / hsgRNA-hVEGFA1 with tBE or tBE variants containing the indicated double AA changes. (B): Editing efficiency induced by the original tBE and tBE variants in (A) with sgRNA-hVEGFA1 / hsgRNA-hVEGFA1.
[0018] Figure 3 The editing efficiency induced by tBE-Y35D with sgRNA / hsgRNA pairs targeting different genomic sites is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA / hsgRNA pairs with tBE or tBE-Y35D. (B): Editing efficiency induced by tBE and tBE-Y35D with sgRNA / hsgRNA pairs at the indicated target sites.
[0019] Figure 4 The editing efficiency induced by tBE-K40H-W102Y with sgRNA / hsgRNA pairs targeting different genomic sites is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA / hsgRNA pairs with tBE or tBE-K40H-W102Y. (B): Editing efficiency induced by tBE and tBE-K40H-W102Y with sgRNA / hsgRNA pairs at the indicated target sites.
[0020] Figure 5 The editing efficiency induced by tBE-K40H-W102Y with sgRNA / hsgRNA pairs targeting more genomic sites is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA / hsgRNA pairs with tBE or tBE-K40H-W102Y. (B): Editing efficiency induced by tBE and tBE-K40H-W102Y with sgRNA / hsgRNA pairs at the indicated target sites.
[0021] Figure 6 The editing windows of tBE-Y35D and tBE-K40H-W102Y are shown. (A): The major editing window of tBE-Y35D spans from position 6 to 8, counting the protospacer adjacent motif (PAM) distal position in the target site as 1. (B): The major editing window of tBE-K40H-W102Y spans from position 4 to 8, counting the protospacer adjacent motif (PAM) distal position in the target site as 1. The area between the two dashed lines is the major editing window for each tBE.
[0022] Figure 7The editing efficiency induced by tBE-H71E and tBE-E73A with sgRNA / hsgRNA pairs targeting different genomic sites is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA / hsgRNA pairs with tBE, tBE-H71E or tBE-E73A. (B): Editing efficiency induced by tBE, tBE-H71E and tBE-E73A with sgRNA / hsgRNA pairs at the indicated target sites.
[0023] Figure 8 The editing efficiency induced by sgRNA-hFANCF / hsgRNA-hFANCF or sgRNA-hHBG / hsgRNA-hHBG and tBE with different types of nCas9-UGI proteins is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA-hFANCF / hsgRNA-hFANCF or sgRNA-hHBG / hsgRNA-hHBG with tBE and different types of nCas9-UGI proteins. (B): Editing efficiency induced by different types of nCas9-UGI proteins and the original tBE in (A) with sgRNA-hFANCF / hsgRNA-hFANCF or sgRNA-hHBG / hsgRNA-hHBG.
[0024] Fig. 9 The editing induced by sgRNA-hBCL11A / hsgRNA-hBCL11A or sgRNA-hVEGFA2-a / hsgRNA-hVEGFA2-a and tBE with different types of nCas9-UGI proteins is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA-hBCL11A / hsgRNA-hBCL11A or sgRNA-hVEGFA2-a / hsgRNA-hVEGFA2-a with tBE and different types of nCas9-UGI proteins. (B): Editing efficiency induced by different types of nCas9-UGI proteins and the original tBE in (A) with sgRNA-hBCL11A / hsgRNA-hBCL11A or sgRNA-hVEGFA2-a / hsgRNA-hVEGFA2-a.
[0025] Fig.10The editing efficiency induced by sgRNA-hCD33-AG-15 / hsgRNA-hCD33-AG-15 or sgRNA-hCD123-CGA-6 / hsgRNA-hCD123-CGA-6 and tBE with different types of nCas9-UGI proteins is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA-hCD33-AG-15 / hsgRNA-hCD33-AG-15 or sgRNA-hCD123-CGA-6 / hsgRNA-hCD123-CGA-6 with tBE and different types of nCas9-UGI proteins. (B): Editing efficiency induced by different types of nCas9-UGI proteins and the original tBE in (A) with sgRNA-hCD33-AG-15 / hsgRNA-hCD33-AG-15 or sgRNA-hCD123-CGA-6 / hsgRNA-hCD123-CGA-6.
[0026] Fig.11 The editing efficiency induced by sgRNA-hPCSK9-TGG-2 / hsgRNA-hPCSK9-TGG-2 or sgRNA-hMSSK1-Mb / hsgRNA-hMSSK1-Mb and tBE with different types of nCas9-UGI proteins is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA-hPCSK9-TGG-2 / hsgRNA-hPCSK9-TGG-2 or sgRNA-hMSSK1-Mb / hsgRNA-hMSSK1-Mb with tBE and different types of nCas9-UGI proteins. (B): Editing efficiency induced by different types of nCas9-UGI proteins and the original tBE in (A) with sgRNA-hPCSK9-TGG-2 / hsgRNA-hPCSK9-TGG-2 or sgRNA-hMSSK1-Mb / hsgRNA-hMSSK1-Mb.
[0027] Fig.12The editing efficiency induced by sgRNA-hHAO1-CAG-2 / hsgRNA-hHAO1-CAG-2 or sgRNA-hCD45-CAA-1 / hsgRNA-hCD45-CAA-1 and tBE with different types of nCas9-UGI proteins is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA-hHAO1-CAG-2 / hsgRNA-hHAO1-CAG-2 or sgRNA-hCD45-CAA-1 / hsgRNA-hCD45-CAA-1 with tBE and different types of nCas9-UGI proteins. (B): Editing efficiency induced by different types of nCas9-UGI proteins and the original tBE in (A) with sgRNA-hHAO1-CAG-2 / hsgRNA-hHAO1-CAG-2 or sgRNA-hCD45-CAA-1 / hsgRNA-hCD45-CAA-1.
[0028] Fig.13 Results of the analysis of the editing efficiency induced by different sgRNA / hsgRNA pairs and tBE with different types of nCas9-UGI proteins are shown. (A): Schematic diagram illustrating the co-transfection of different sgRNA / hsgRNA pairs with tBE and different types of nCas9-UGI proteins. (B): Editing efficiencies induced by different types of nCas9-UGI proteins and the original tBE in (A) with different sgRNA / hsgRNA pairs at the specified target sites were calculated by EditR analysis. (C): Statistical analysis of the normalized editing frequencies at all 10 targeted sites shown in B. (D): Statistical analysis of the C / G to T / A editing scores at all 10 targeted sites shown in B.
[0029] Fig.14 The editing efficiency induced by tBE, tBE-IRES-TEVC, or tBE-IRES-TEVN with nCas9 and 4 different sgRNA / hsgRNA pairs targeting different genomic sites is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA / hsgRNA pairs with tBE, tBE-IRES-TEVC, or tBE-IRES-TEVN. (B): Editing efficiency induced by tBE, tBE-IRES-TEVC, or tBE-IRES-TEVN in (A) with sgRNA / hsgRNA pairs at the indicated target sites.
[0030] Fig.15The editing efficiency induced by tBE, tBE-IRES-TEVC, or tBE-IRES-TEVN with nCas9 and 4 different sgRNA / hsgRNA pairs targeting different genomic sites is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA / hsgRNA pairs with tBE, tBE-IRES-TEVC, or tBE-IRES-TEVN. (B): Editing efficiency induced by tBE, tBE-IRES-TEVC, or tBE-IRES-TEVN in (A) with sgRNA / hsgRNA pairs at the indicated target sites.
[0031] Fig.16 The editing efficiency induced by tBE, tBE-IRES-TEVC, or tBE-IRES-TEVN with nCas9 and sgRNA-hPCSK9-TGG-11 / hsgRNA-hPCSK9-TGG-11 is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA / hsgRNA pairs with tBE, tBE-IRES-TEVC, or tBE-IRES-TEVN. (B): Editing efficiency induced by tBE, tBE-IRES-TEVC, or tBE-IRES-TEVN with sgRNA-hPCSK9-TGG-11 / hsgRNA-hPCSK9-TGG-11 in (A). (C): Editing efficiency induced by tBE, tBE-IRES-TEVC, or tBE-IRES-TEVN with nCas9 and different sgRNA / hsgRNA pairs at each target site was calculated by EditR analysis.
[0032] Fig.17 The editing efficiency induced by tBE or tBE-IRES-TEVN with nCas9 and different sgRNA / hsgRNA pairs targeting three HBV genomic sites in Lenti-HBV HepG2 stable cell line is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA / hsgRNA pairs with tBE or tBE-IRES-TEVN. (B): Editing efficiency induced by tBE or tBE-IRES-TEVN with sgRNA / hsgRNA pairs in (A) at the indicated target sites. (C): Editing efficiency induced by tBE or tBE-IRES-TEVN with nCas9 and different sgRNA / hsgRNA pairs at each target site was calculated by EditR analysis.
[0033] Fig.18The editing efficiency induced by tBE or tBE-IRES-TEVN with nCas9 and different sgRNA / hsgRNA pairs targeting three HBV genomic sites in Lenti-HBV 293FT stable cell line is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA / hsgRNA pairs with tBE or tBE-IRES-TEVN. (B): Editing efficiency induced by tBE or tBE-IRES-TEVN with sgRNA / hsgRNA pairs in (A) at the indicated target sites. (C): Editing efficiency induced by tBE or tBE-IRES-TEVN with nCas9 and different sgRNA / hsgRNA pairs at each target site was calculated by EditR analysis.
[0034] Fig.19 The editing efficiency induced by tBE or tBE-IRES-TEVN with nCas9 and targeting 1PCSK9 genomic site in Hepa1-6 cell line is shown. (A): Schematic diagram illustrating the co-transfection of sgRNA-mPCSK9-TGG-3 / hsgRNA-mPCSK9-TGG-3 pair with tBE or tBE-IRES-TEVN in wild-type Hepa1-6 by RNA electroporation. (B): Editing efficiency induced by tBE or tBE-IRES-TEVN with sgRNA / hsgRNA pairs in (A) at the indicated target sites. (C): Editing efficiency induced by tBE or tBE-IRES-TEVN with nCas9 and different sgRNA / hsgRNA pairs at each target site was calculated by EditR analysis. DETAILED DESCRIPTION definition
[0035] It should be noted that the term "a" or "an" entity refers to one or more entities in that entity; for example, "antibody" should be understood to represent one or more antibodies. Therefore, the terms "a" (or "an"), "one or more" and "at least one" are used interchangeably herein.
[0036] As used herein, the term "polypeptide" is intended to include the singular "polypeptide" as well as the plural "polypeptide", and refers to a molecule consisting of monomers (amino acids) linearly connected by amide bonds (also called peptide bonds). The term "polypeptide" refers to any one or more chains composed of two or more amino acids, and does not refer to the specific length of the product. Therefore, peptides, dipeptides, tripeptides, oligopeptides, "proteins", "amino acid chains" or any other terms used to refer to one or more chains of two or more amino acids are included in the definition of "polypeptide", and the term "polypeptide" can replace any of these terms or can be used interchangeably with any of these terms. The term "polypeptide" is also intended to refer to the product of post-expression modification of the polypeptide, and post-expression modification includes but is not limited to glycosylation, acetylation, phosphorylation, amination, derivatization by known protection / blocking groups, proteolytic cleavage or modification by non-naturally occurring amino acids. The polypeptide can be derived from a natural biological source or produced by recombinant technology, but is not necessarily translated from a specified nucleic acid sequence. It can be produced in any way, including by chemical synthesis.
[0037] "Homology" or "identity" or "similarity" refers to the sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing positions in each sequence that can be aligned for the purpose of comparison. When a position in the compared sequences is occupied by the same base or amino acid, then the molecules are homologous at that position. The degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences. "Unrelated" or "non-homologous" sequences share less than 40% identity with one of the sequences of the present disclosure, but preferably less than 25% identity.
[0038] A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) having a certain percentage (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%) of "sequence identity" to another sequence means that, when aligned, the percentage of bases (or amino acids) is the same when comparing the two sequences. Such alignments and percent homology or percent sequence identity can be determined using software programs known in the art, such as those described in Ausubel et al., eds. (2007), "Current Protocols in Molecular Biology". Preferably, default parameters are used for alignment. One alignment program is BLAST, using default parameters.
[0039] The term "equivalent nucleic acid or polynucleotide" refers to a nucleic acid having a nucleotide sequence with a certain degree of homology or sequence identity to the nucleotide sequence of a nucleic acid or its complement. The homologue of a double-stranded nucleic acid is intended to include a nucleic acid having a nucleotide sequence with a certain degree of homology to it or to its complementary sequence. In one aspect, a homologue of a nucleic acid can hybridize with a nucleic acid or its complement. Similarly, an "equivalent polypeptide" refers to a polypeptide with a certain degree of homology or sequence identity to the amino acid sequence of a reference polypeptide. In some aspects, the sequence identity is at least about 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99%. In some aspects, compared with a reference polypeptide or polynucleotide, an equivalent polypeptide or polynucleotide has one, two, three, four or five additions, deletions, substitutions and combinations thereof. In some aspects, an equivalent sequence retains the activity (e.g., epitope binding) or structure (e.g., salt bridge) of a reference sequence.
[0040] The term "encoding" when applied to a polynucleotide means that if the polynucleotide can be transcribed and / or translated to produce mRNA of the polypeptide and / or its fragments in its native state or when manipulated by methods well known to those skilled in the art, then the polynucleotide is said to "encode" a polypeptide. The antisense strand is the complementary strand of such nucleic acid, and the coding sequence can be deduced therefrom. Mutated cytosine deaminase with narrowed editing window
[0041] Off-target editing by genome editing systems can cause serious side effects in target organisms and should therefore be minimized or avoided. However, current genome editing tools, such as the CRISPR / Cas9 system, base editors, and primer editors, are associated with frequent off-target editing.
[0042] The inventors have developed a new base editing system, the variant base editor (tBE), which can specifically edit cytosine in the target region without observable off-target mutations. The tBE system combines conventional cytosine deaminase (or its catalytic domain) with a cleavable cytosine deaminase inhibitor (dCDI). tBE remains inactive at off-target sites, and cleaving dCDI at the target site activates the catalytic domain for precise editing.
[0043] In addition to off-target editing, bystander mutations of base editing systems are also unwanted base changes in the editing window. Bystander mutations can compromise the editing site precision of base editing systems and should be minimized when performing precise base editing. Therefore, new tBE systems with narrowed editing windows that can reduce bystander mutations are needed.
[0044] A commonly used cytosine deaminase is mouse APOBEC3 (mA3) protein (Access#: NP_001153887.1). It includes a catalytic portion mA3CDA1 and an inhibitory portion mA3CDA2. As shown in Table 1, the CDA1 portion includes residues 35 to 141 of SEQ ID NO: 1 (underlined; SEQ ID NO: 2), and the CDA2 portion includes residues 208 to 429 of SEQ ID NO: 1 (bold; SEQ ID NO: 6). Table 1. mAPOBEC3 sequences
[0045] Through careful design and testing, the inventors found that when certain amino acid residues in the mA3CDA1 domain are mutated, the resulting base editor has a narrowed editing window while maintaining high editing efficiency. Such amino acid residues include Y35, K37, R39, K40, N66, W102 and Y132. These residues can be mutated individually, or two or more of them can be mutated together. The single mutations tested include Y35D, K37D, R39A, K40A, N66G, W102Y, W102F and Y132F, and the double mutations tested include R39A-K40H, R39A-N66A, K40H-W102Y, N66A-W102Y, N66Q-W102Y, K40H-Y132F, N66A-Y132F, N66Q-Y132F, K40A-N66A, K40A-N66Q and K40H-N66G. Based on the test results, additional mutations are also considered. For example, Y35E is expected to be similar to Y35D. These mutations (replacements) are summarized in Table 2 below. Table 2. mAPOBEC3 substitutions
[0046] Therefore, according to one embodiment of the present disclosure, a mutant mA3CDA1 domain (or a protein comprising the mutant mA3CDA1 domain) is provided. In one embodiment, the mutant mA3CDA1 domain is similar to the wild-type mA3CDA1 domain and has, for example, at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity thereto. The wild-type mA3CDA1 domain comprises amino acid residues 35-141 (SEQ ID NO: 2) of the mouse mA3 protein (SEQ ID NO: 1).
[0047] In some embodiments, the mutated mA3CDA1 domain retains wild-type amino acid residues known to be important for the catalytic activity of the domain. Examples include residues H71 and E73. In some embodiments, wild-type residues at D41, F43, F64, A72, P104, C105, and C108 are retained.
[0048] In some embodiments, the mutant mA3CDA1 domain comprises one or more substitutions shown in Table 2 and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by this specific substitution.
[0049] In some embodiments, the mutated mA3CDA1 domain comprises the substitution Y35D and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutated mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutated mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutated mA3CDA1 domain differs from SEQ ID NO: 2 only by this specific substitution. In some embodiments, the mutated mA3CDA1 domain comprises the sequence of SEQ ID NO: 3.
[0050] In some embodiments, the mutant mA3CDA1 domain comprises the substitution Y35E and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by this specific substitution. In some embodiments, the mutant mA3CDA1 domain comprises the sequence of SEQ ID NO: 4.
[0051] In some embodiments, the mutant mA3CDA1 domain comprises the substitution K37D (or K37E) and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by this specific substitution.
[0052] In some embodiments, the mutant mA3CDA1 domain comprises the substitution R39A (or R39G, R39I, R39L, or R39V) and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by this specific substitution.
[0053] In some embodiments, the mutant mA3CDA1 domain comprises the substitution K40A (or K40G, K40I, K40L, K40V, or K40H) and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by this specific substitution.
[0054] In some embodiments, the mutant mA3CDA1 domain comprises the substitution N66G (or N66A, N66I, N66L, N66V, or V66Q) and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by this specific substitution.
[0055] In some embodiments, the mutant mA3CDA1 domain comprises the substitution W102Y (or W102F) and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by this specific substitution.
[0056] In some embodiments, the mutant mA3CDA1 domain comprises the substitution Y132F (or Y132W) and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by this specific substitution.
[0057] In some embodiments, the mutant mA3CDA1 domain comprises substitutions K40H-W102Y and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO:1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO:1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO:2 only in these specific substitutions. In some embodiments, the mutant mA3CDA1 domain comprises the sequence of SEQ ID NO:5.
[0058] In some embodiments, the mutant mA3CDA1 domain comprises substitutions R39A-K40H and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by these specific substitutions.
[0059] In some embodiments, the mutant mA3CDA1 domain comprises substitutions R39A-N66A and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by these specific substitutions.
[0060] In some embodiments, the mutant mA3CDA1 domain comprises substitutions N66A-W102Y and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by these specific substitutions.
[0061] In some embodiments, the mutant mA3CDA1 domain comprises substitutions N66Q-W102Y and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by these specific substitutions.
[0062] In some embodiments, the mutant mA3CDA1 domain comprises substitutions K40H-Y132F and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by these specific substitutions.
[0063] In some embodiments, the mutant mA3CDA1 domain comprises substitutions N66A-Y132F and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by these specific substitutions.
[0064] In some embodiments, the mutant mA3CDA1 domain comprises substitutions N66Q-Y132F and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by these specific substitutions.
[0065] In some embodiments, the mutant mA3CDA1 domain comprises substitutions K40A-N66A and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by these specific substitutions.
[0066] In some embodiments, the mutant mA3CDA1 domain comprises substitutions K40A-N66Q and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by these specific substitutions.
[0067] In some embodiments, the mutant mA3CDA1 domain comprises substitutions K40H-N66G and has at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to the wild-type mA3CDA1 domain. In some embodiments, the mutant mA3CDA1 domain retains residues H71 and E73 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain retains residues D41, F43, F64, A72, P104, C105, and C108 of SEQ ID NO: 1. In some embodiments, the mutant mA3CDA1 domain differs from SEQ ID NO: 2 only by these specific substitutions. Fusion proteins and base editors
[0068] The mutated mA3CDA1 domains disclosed herein can be incorporated into base editors that can be used to achieve precise base editing. In one embodiment, a fusion protein comprising a first fragment and a second fragment is provided, the first fragment comprising a mutated mA3CDA1 domain, the second fragment comprising a nucleobase deaminase inhibitor. In some embodiments, a protease cleavage site is included between the first fragment and the second fragment in the fusion protein.
[0069] Thus, a "nucleobase deaminase inhibitor" refers to a protein or protein domain that inhibits the deaminase activity of a nucleobase deaminase. In some embodiments, the second fragment includes at least one inhibitory core of an inhibitory protein / domain.
[0070] Non-limiting exemplary nucleobase deaminase inhibitors include mA3-CDA2, hA3F-CDA1, and hA3B-CDA1 (sequences of which are provided in Table 3), which are inhibitory domains of the corresponding nucleobase deaminases. Additional nucleobase deaminase inhibitors have been identified as homologs of mA3-CDA2, hA3F-CDA1, or hA3B-CDA1 in the protein database (see Table 3A, Table 3B, and Table 3C). Their biological equivalents (e.g., having at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, 99.5% sequence identity, or having one, two, or three amino acid additions / deletions / substitutions, and having nucleobase deaminase inhibitor activity) can also be prepared using methods known in the art, such as conservative amino acid substitutions.
[0071] When a nucleobase deaminase inhibitor is included, the nucleobase deaminase inhibitor is fused to the nucleobase deaminase but is separable by the protease cleavage site. In some embodiments, the base editing system further comprises a protease capable of cleaving the protease cleavage site.
[0072] The protease cleavage site can be any known protease cleavage site (peptide) of any protease. Non-limiting examples of proteases include TEV protease, TuMV protease, PPV protease, PVY protease, ZIKV protease and WNV protease. In some embodiments, the protease cleavage site is not the cleavage site of trypsin, chymotrypsin or furin. The protein sequences of exemplary proteases and their corresponding cleavage sites are provided in Table 3. Table 3. Exemplary sequences Table 3A: mA3CDA2 core sequence related domains Table 3B: hA3FCDA1 core sequence related domains Table 3C: hA3BCDA1 related domains
[0073] In some embodiments, the protease cleavage site is a self-cleaving peptide, such as a 2A peptide. A "2A peptide" is a viral oligopeptide of 18 to 22 amino acids long that mediates "cleavage" of a polypeptide during translation in a eukaryotic cell. The name "2A" refers to a specific region of the viral genome, and different viral 2As are usually named after the viruses from which they are derived. The first 2A discovered was F2A (foot-and-mouth disease virus), after which E2A (equine rhinitis A virus), P2A (porcine Teschovirus-1 2A) and T2A (Typha striata virus 2A) were also identified. Several non-limiting examples of 2A peptides are provided in SEQ ID NOs: 33-35.
[0074] In some embodiments, the protease cleavage site is a cleavage site of a TEV protease (e.g., SEQ ID NO: 12). In some embodiments, the TEV protease provided in the base editing system comprises two separate fragments, each of which is inactive by itself. However, in the presence of the remaining fragments of the TEV protease, they will be able to perform cleavage. This arrangement provides additional control and flexibility of base editing capabilities. The TEV fragment can be a TEV N-terminal domain (e.g., SEQ ID NO: 10) or a TEV C-terminal domain (e.g., SEQ ID NO: 11).
[0075] In some embodiments, a fusion protein comprising a mutated mA3CDA1 domain (optionally with a deaminase inhibitor) and a Cas protein is provided.
[0076] The term "Cas protein" or "Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) protein" refers to an RNA-guided DNA endonuclease associated with the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) adaptive immune system in Streptococcus pyogenes and other bacteria. Cas proteins include Cas9 proteins, Cas12a (Cpf1) proteins, Cas12b (formerly known as C2c1) proteins, Cas13 proteins, and various engineered counterparts. Examples of Cas proteins include SpCas9, FnCas9, St1Cas9, St3Cas9, NmCas9, SaCas9, AsCpf1, LbCpf1, FnCpf1, VQR SpCas9, EQR SpCas9, VRER SpCas9, SpCas9-NG, xSpCas9, RHA FnCas9, KKHSaCas9, NmeCas9, StCas9, CjCas9, AsCpf1, FnCpf1, SsCpf1, PcCpf1, BpCpf1, CmtCpf1, LiCpf1, PmCpf1, Pb3310Cpf1, P b4417Cpf1, BsCpf1, EeCpf1, BhCas12b, AkCas12b, EbCas12b, LsCas12b, RfCas13d, LwaCas13a, PspCas13b, PguCas13b and RanCas13b.
[0077] In some embodiments, a peptide linker is optionally provided between each fragment in the fusion protein. In some embodiments, a peptide linker has 1 to 100 amino acid residues (or 3 to 20, 4 to 15, but not limited thereto). In some embodiments, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the amino acid residues of a peptide linker are selected from the amino acid residues of alanine, glycine, cysteine and serine.
[0078] Improved base editing systems are also provided. In one embodiment, the base editing system comprises (a) a first fusion protein comprising a nucleobase deaminase (e.g., a mutant mA3CDA1), a nucleobase deaminase inhibitor (e.g., mA3CDA2), and a first RNA recognition peptide (e.g., MCP), wherein the nucleobase deaminase and the nucleobase deaminase inhibitor are separated by a protease cleavage site (e.g., a TEV site), which is capable of being cleaved by a protease (e.g., TEV); (b) a second fusion protein comprising a second RNA recognition peptide different from the first RNA recognition peptide (e.g., N22p) fused to an inactive portion of the protease (e.g., TEVc); (c) a second portion of the protease (e.g., TEVn), the second portion in combination with the first portion enabling the protease activity to cleave the protease cleavage site; (d) an auxiliary sgRNA, the auxiliary sgRNA further comprising a first RNA recognition site (e.g., MS2) that can be recognized by the first RNA recognition peptide; (e) an sgRNA, the sgRNA further comprising a second RNA recognition site (e.g., boxB) that can be recognized by the second RNA recognition peptide; and (f) a Cas protein. In some embodiments, the nucleobase deaminase is a mutant protein of the present disclosure.
[0079] In some embodiments, the first fusion protein further comprises one, two or three uracil glycosylase inhibitors (UGIs). In some embodiments, the Cas protein further comprises one, two or three UGIs, wherein the UGIs can be cut from the Cas protein to become independent UGIs (e.g., each is separate).
[0080] Polynucleotides encoding portions of the base editing system are also provided. In one embodiment, a polynucleotide is provided, the polynucleotide comprising: a first fragment, the first fragment encoding (a) a first fusion protein, the first fusion protein comprising a nucleobase deaminase, a nucleobase deaminase inhibitor and a first RNA recognition peptide, wherein the nucleobase deaminase and the nucleobase deaminase inhibitor are separated by a protease cleavage site, the protease cleavage site being capable of being cleaved by a protease; a second fragment, the second fragment encoding (b) a second fusion protein, the second fusion protein comprising an inactive portion of the protease fused to a second RNA recognition peptide different from the first RNA recognition peptide; a third fragment, the third fragment encoding (c) a second portion of the protease, the second portion in combination with the first portion being capable of achieving the protease activity to cleave the protease cleavage site; a fourth fragment, the fourth fragment encoding (d) an auxiliary sgRNA, the auxiliary sgRNA further comprising a first RNA recognition site capable of being recognized by the first RNA recognition peptide; and a fifth fragment, the fifth fragment encoding (e) an sgRNA, the sgRNA further comprising a second RNA recognition site capable of being recognized by the second RNA recognition peptide, wherein the first fragment, the second fragment and the third fragment are configured to be transcribed into a single mRNA molecule.
[0081] In some embodiments, the first fragment and the second fragment are separated by a first separating sequence encoding a first internal ribosome entry site (IRES, e.g., SEQ ID NO: 36), and the second fragment and the third fragment are separated by a second separating sequence encoding a first self-cleaving peptide. Alternatively, in some embodiments, the first fragment and the second fragment are separated by a first separating sequence encoding a second self-cleaving peptide, and the second fragment and the third fragment are separated by a second separating sequence encoding a second internal ribosome entry site (IRES, e.g., SEQ ID NO: 36). In some embodiments, the nucleobase deaminase is a mutant protein of the present disclosure.
[0082] In some embodiments, such as Fig.14 As shown, each of the fourth segment and the fifth segment regulates and / or transcribes separately from each other. In some embodiments, another polynucleotide encoding a Cas protein is provided. In some embodiments, the Cas protein is fused to one or more UGI sequences.
[0083] For any fusion protein of the present disclosure, its biological equivalent is also provided. In some embodiments, the biological equivalent has at least about 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity with the reference fusion protein. Preferably, the biological equivalent retains the required activity of the reference fusion protein. In some embodiments, the biological equivalent is derived by comprising one, two, three, four, five or more amino acid additions, deletions, substitutions or their combinations. In some embodiments, the substitution is a conservative amino acid substitution.
[0084] "Conservative amino acid substitutions" refer to substitutions in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a non-essential amino acid residue in an immunoglobulin polypeptide is preferably replaced by another amino acid residue from the same side chain family. In another embodiment, an amino acid string may be replaced by a structurally similar string that differs in the order and / or composition of the side chain family members.
[0085] Base editors containing such fusion proteins have reduced or even no editing ability and will therefore produce reduced or no off-target mutations. After cleavage of the protease cleavage site at the target site and release of the nucleobase deaminase inhibitor from the fusion protein, the base editor located at the target site will be able to effectively edit the target site.
[0086] An exemplary base editor is tBE, which employs a dual sgRNA system in which an auxiliary sgRNA (hsgRNA) is used to target a site close to the primary target site. In tBE, the nucleobase deaminase inhibitor is only released when both sgRNAs bind to the target sequence, ensuring that the nucleobase deaminase is not edited at off-target sites.
[0087] The first molecule can include only Cas protein, which has a size suitable for packaging in a common vector AAV. The second molecule includes a nucleobase deaminase (e.g., a mutated mA3CDA1), a nucleobase deaminase inhibitor (e.g., mA3CDA2), and an RNA recognition peptide (e.g., MCP), etc. A protease cleavage site (e.g., a TEV site) is inserted between the nucleobase deaminase and the nucleobase deaminase inhibitor, which enables the nucleobase deaminase inhibitor to be removed at an appropriate time / position. Optionally, the second molecule also includes UGI.
[0088] The third molecule is a fusion between an inactive portion of a protease (e.g., TEVc) fused to a different RNA recognition peptide (e.g., N22p). The fourth molecule is an independent TEVn that, in combination with the first portion, enables protease activity to remove the nucleobase deaminase inhibitor from the second molecule.
[0089] The fifth molecule is an auxiliary sgRNA, which contains an RNA recognition site (e.g., MS2) that can be recognized by the RNA recognition peptide in the second molecule. The sixth molecule is a conventional sgRNA, which contains an RNA recognition site (e.g., boxB) that can be recognized by the RNA recognition peptide in the third molecule.
[0090] At the correct target site in the genome (or RNA), both hsgRNA and sgRNA will bind, and each will recruit Cas proteins to the binding site. The hsgRNA will also recruit a second molecule by MS2-MCP binding, and the sgRNA will recruit a third molecule by boxB-N22p binding. Therefore, the TEVc of the third molecule contacts the TEV site. Since independent TEVn is present throughout the cell, it can also be present here, which ensures that TEVc is active and the nucleobase deaminase inhibitor is cut by the nucleobase deaminase in molecule 2, thereby activating the nucleobase deaminase.
[0091] In some embodiments, one or more proteins can be encoded by a single mRNA or construct, while being separated by a sequence encoding a 2A peptide (e.g., SEQ ID NO: 33, 34, or 35) or an internal ribosome entry site (IRES) (e.g., SEQ ID NO: 36). In some embodiments, one or more (e.g., 1, 2, or 3) free UGI sequences are generated from the molecule.
[0092] In some embodiments, the distance between the hsgRNA binding site and the conventional sgRNA binding site is 34 bp to 91 bp (from PAM to PAM), where the hsgRNA is located upstream.
[0093] In one embodiment, a dual guide RNA system is also provided. In some embodiments, the system comprises: a target single guide RNA, the target single guide RNA comprising a first spacer having sequence complementarity with a target nucleic acid sequence adjacent to a first PAM site, an auxiliary single guide RNA, the auxiliary single guide RNA comprising a second spacer having sequence complementarity with a second nucleic acid sequence adjacent to a second PAM site, a clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) protein, and a mutant mA3CDA1 (or a corresponding fusion protein as disclosed herein).
[0094] In some embodiments, the second PAM site is located within 150 bases from the second PAM site, or alternatively within 140, 130, 120, 110, 100, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80, 75 or 70 bases. In some embodiments, the second PAM site is located at least 10 bases from the first PAM, or alternatively at least 15, 20, 25, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55 or 60 bases. In some embodiments, the second PAM site is upstream of the first PAM site. In some embodiments, the second PAM site is downstream of the first PAM site. In some embodiments, the distance is 20 to 100, 25 to 95, 30 to 95, 34 to 95, 34 to 91, 34 to 90, 35 to 90, 40 to 90, 40 to 84, 45 to 85, or 50 to 80 bases, but is not limited thereto.
[0095] In some embodiments, the length of the second (auxiliary) spacer is 8 to 15 bases. In some embodiments, the length of the second spacer is 8 to 14, 8 to 13, 8 to 12, 8 to 11, 8 to 10, 9 to 15, 9 to 14, 9 to 13, 9 to 12, 9 to 11, 9 to 10, 10 to 15, 10 to 14, 10 to 13, 10 to 12, 10 to 11, 11 to 15, 11 to 14, 11 to 13, 11 to 12, 12 to 15, 12 to 14, 12 to 13, or 13 to 15 bases. In contrast, the length of the first spacer is at least 16, 17, 18, or 19 bases. method
[0096] The base editors and base editing methods described in this disclosure can be used to perform high-specificity and high-efficiency base editing in the genomes of various eukaryotic organisms.
[0097] In one embodiment, the present disclosure provides a method for introducing a C to T substitution at a cytosine in a target nucleic acid. In some embodiments, the method requires contacting the target nucleic acid with a CRISPR-associated (Cas) protein, a mutated mA3CDA1 as disclosed herein (or a corresponding fusion protein as disclosed herein), a single guide RNA (sgRNA), and a helper single guide RNA (hsgRNA), wherein the sgRNA and the hsgRNA are capable of hybridizing to the target nucleic acid.
[0098] In some embodiments, the mutant mA3CDA1 has a Y35D or Y35E mutation. In some embodiments, the sgRNA is designed such that a cytosine is located between nucleotides 6 and 8 of the 3' end of a protospacer adjacent motif (PAM) sequence on the target nucleic acid sequence.
[0099] In some embodiments, the mutant mA3CDA1 has K40H and W102Y mutations. In some embodiments, the sgRNA is designed such that a cytosine is located between nucleotides 4 and 8 at the 3' end of a protospacer adjacent motif (PAM) sequence on a target nucleic acid sequence.
[0100] The contact between the fusion protein (and guide RNA) and the target polynucleotide can be in vitro, particularly in cell culture. When the contact is ex vivo or in vivo, the fusion protein can show clinical / therapeutic significance. In vivo contact can be administration to a living subject, such as a human, an animal, a yeast, a plant, a bacterium, a virus, but is not limited thereto. Example Example 1. Mutated mA3 catalytic domain
[0101] The inventors have developed a new base editing system, the variant base editor (tBE), which can specifically edit cytosine in the target region without observable off-target mutations. The tBE system consists of a cytosine deaminase inhibitor (dCDI) and a split TEV system. tBE is able to remain inactive at off-target sites due to its cleavable dCDI domain fusion, thereby eliminating unexpected mutations. Only when bound to the targeted site is tBE converted to excise the dCDI domain and catalyze targeted deamination for precise editing. More specifically, tBE uses sgRNA (usually 20nt) to bind to the target genomic site, and uses auxiliary sgRNA (hsgRNA, usually 10nt or 20nt) to bind to the adjacent region upstream of the target genomic site. The combination of two sgRNAs can guide the components of the tBE system to assemble correctly at the target genomic site for base editing.
[0102] After analyzing the editable positions at different target sites, we confirmed that the editing window of tBE spans from position 3 to position 9 (the protospacer adjacent motif (PAM) distal position in the target site is counted as 1). It is desirable to develop new tBEs with narrower editing windows.
[0103] Through structural studies and computer simulations, we selected residues Y35, K37, R39, K40, N66, W102, and Y132 in the catalytic domain of mA3CDA1 for mutation. In the first round, single mutations were tested, including Y35D, K37D, R39A, K40A, N66G, W102Y, W102F, and Y132F.
[0104] The mutant mA3CDA1 was introduced into the tBE (mA3CDA1+mA3CDA2) system. The resulting base editors tBE-Y35D, tBE-K37D, tBE-R39A, tBE-K40A, tBE-N66G, tBE-W102Y, tBE-W102F, and tBE-Y132F were tested with sgRNA and hsgRNA targeting the human VEGFA1 gene. Figure 1 As shown, these single residue substitutions in the mA3CDA1 region narrowed the editing window, thereby improving the editing precision of tBE.
[0105] Double mutations of mA3CDA1 were also tested, including R39A-K40H, R39A-N66A, K40H-W102Y, N66A-W102Y, N66Q-W102Y, K40H-Y132F, N66A-Y132F, N66Q-Y132F, K40A-N66A, K40A-N66Q, and K40H-N66G. The resulting base editors tBE-R39A-K40H, tBE-R39A-N66A, tBE-K40H-W102Y, tBE-N66A-W102Y, tBE-N66Q-W102Y, tBE-K40H-Y132F, tBE-N66A-Y132F, tBE-N66Q-Y132F, tBE-K40A-N66A, tBE-K40A-N66Q, and tBE-K40H-N66G were also tested on the human VEGFA1 gene. Figure 2 As shown, these double mutant mA3CDA1 also resulted in a narrower editing window, thereby improving the editing precision of tBE.
[0106] The base editor tBE-Y35D appeared to have the narrowest editing window and high editing efficiency. Therefore, it was further tested with more target sites, including CD123, RAG1, SPI, and BCL11A. Figure 3As shown, the editing window of tBE-Y35D spans from the 6th to the 8th bit ( Figure 3 and Figure 6 (A)), which is smaller than the editing window of the original tBE (from position 3 to position 9).
[0107] Among the tBE variants with double mutations, tBE-K40H-W102Y has the narrowest editing window while maintaining high editing efficiency. After analyzing more editable positions at the target site, we found that the editing window of tBE-K40H-W102Y spans from position 4 to position 8 ( Figure 4 , Figure 5 and Figure 6 (B)), which is smaller than the editing window of the original tBE (from position 3 to position 9).
[0108] This example further tested which residues were important for retaining the catalytic activity of the mA3CDA1 protein. Through screening, residues H71 and E73 were determined to be important residues. Figure 7 As shown, the editing efficiency of the mutants tBE-H71E and tBE-E73A at the target site was almost abolished, indicating that H71 and E73 are essential for the catalytic activity of mA3CDA1. Example 2. Further improved base editors with fused and / or independent UGIs
[0109] To further improve the editing efficiency and fidelity of tBE-mediated base editing, more copies of uracil glycosylase inhibitor (UGI) protein were added to the tBE system.
[0110] The original tBE vector was further co-transfected with different types of nCas9-UGI and showed higher C to T editing efficiency and fidelity, especially nCas9-1×UGI and nCas9-3×Free-UGI ( Figures 8 to 13 We found that nCas9-1×UGI and nCas9-3×Free-UGI suppressed the generation of C to A / C to G substitutions and simultaneously increased the desired C to T editing ( Fig.13 (BD)). Notably, both the UGI type fused with nCas9 and the UGI type without nCas9 can improve the fidelity and efficiency of the tBE system. Example 3. Further improved base editor with IRES
[0111] In the original tBE system, the deaminase and split TEV protease were separated by two 2A peptides to co-express three ORFs under the control of a single promoter.
[0112] It has been found that either of these two 2A peptides can be replaced by an internal ribosome entry site (IRES). Both tBE-IRES-TEVC and tBE-IRES-TEVN induced efficient base editing at the human genomic site ( Figures 14 to 16 In addition, tBE-IRES-TEVN also expressed at the HBV viral genome site ( Fig.17 and Fig.18 ) and mouse genomic loci ( Fig.19 ) induced precise gene editing. ***
[0113] The present disclosure is not limited by the scope of the specific embodiments, which are intended to be a single illustration of the various aspects of the present disclosure, and any compositions or methods that are functionally equivalent are within the scope of the present disclosure. It is apparent to those skilled in the art that various modifications and variations may be made to the methods and compositions of the present disclosure without departing from the essence or scope of the present disclosure. Therefore, the present disclosure is intended to cover modifications and variations of the present disclosure, provided that these modifications and variations are within the scope of the appended claims and their equivalents.
[0114] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Claims
1. A protein comprising a catalytic domain of a mutant mouse APOBEC3 protein, wherein the catalytic domain has at least 85% sequence identity with amino acid residues 35-141 of SEQ ID NO:1 and comprises a substitution at a residue selected from the group consisting of Y35, K37, R39, K40, N66, W102, Y132, and a combination thereof relative to SEQ ID NO:
1.
2. The protein of claim 1, wherein the substitution is selected from the group consisting of:
3. The protein of claim 1 or 2, wherein the catalytic domain retains the amino acids of SEQ ID NO: 1 at residues H71 and E73.
4. The protein of any one of claims 1 to 3, wherein the catalytic domain retains the amino acids of SEQ ID NO: 1 at residues D41, F43, F64, A72, P104, C105 and C108.
5. The protein of any one of claims 1 to 4, wherein the substitution is selected from the group consisting of Y35D, Y35E, K37D, R39A, K40A, K40H, N66A, N66G, N66Q, W102Y, W102F, Y132F, and combinations thereof.
6. The protein of claim 5, wherein the substitution is Y35D or Y35E.
7. The protein of claim 1, wherein the catalytic domain comprises the amino acid sequence of SEQ ID NO:
3.
8. The protein of any one of claims 5, wherein the substitutions are K40H and W102Y.
9. The protein of claim 1, wherein the catalytic domain comprises the amino acid sequence of SEQ ID NO:
5.
10. A fusion protein, comprising: a first fragment comprising the protein according to any one of claims 1 to 9, and A second fragment, wherein the second fragment comprises a nucleobase deaminase inhibitor. The fusion protein according to claim 10 , further comprising a protease cleavage site located between the first fragment and the second fragment.
12. The fusion protein of claim 10 or 11, wherein the nucleobase deaminase inhibitor is an inhibitory domain of a nucleobase deaminase.
13. The fusion protein of claim 10, wherein the nucleobase deaminase inhibitor comprises the amino acid sequence of SEQ ID NO: 7, 8 or 9, or amino acid residues 128-223 of SEQ ID NO:
7.
14. A dual guide RNA system, comprising: a target single guide RNA comprising a first spacer region having sequence complementarity with a target nucleic acid sequence adjacent to a first PAM site, an auxiliary single guide RNA, the auxiliary single guide RNA comprising a second spacer region having sequence complementarity with a second nucleic acid sequence adjacent to a second PAM site, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) proteins, and The protein according to any one of claims 1 to 9 or the fusion protein according to any one of claims 10 to 13.
15. The dual guide RNA system of claim 14, wherein the second PAM site is 34 to 91 bases away from the first PAM site.
16. A method for introducing a C to T substitution at a cytosine in a target nucleic acid, the method comprising contacting the target nucleic acid with a CRISPR-associated (Cas) protein, a protein according to any one of claims 1 to 9, or a fusion protein according to any one of claims 10 to 13, a single guide RNA (sgRNA), and a helper single guide RNA (hsgRNA), wherein the sgRNA and the hsgRNA are capable of hybridizing to the target nucleic acid. 17 . The method of claim 16 , wherein the cytosine is located between the 4th and 8th nucleotides at the 3′ end of a protospacer adjacent motif (PAM) sequence on the target nucleic acid sequence.
18. The method of claim 16, wherein the cytosine is located between the 6th and 8th nucleotides at the 3' end of a protospacer adjacent motif (PAM) sequence on the target nucleic acid sequence.
19. A method for introducing a C to T substitution at a cytosine in a target nucleic acid, the method comprising contacting the target nucleic acid with a CRISPR-associated (Cas) protein, a fusion protein according to any one of claims 10 to 13, a single guide RNA (sgRNA) and a helper single guide RNA (hsgRNA), wherein the sgRNA and the hsgRNA are capable of hybridizing with the target nucleic acid, wherein the cytosine is located between the 6th and 8th nucleotides at the 3' end of a protospacer adjacent motif (PAM) sequence on the target nucleic acid sequence, and wherein the catalytic domain comprises the amino acid sequence of SEQ ID NO:
3.
20. A method for introducing a C to T substitution at a cytosine in a target nucleic acid, the method comprising contacting the target nucleic acid with a CRISPR-associated (Cas) protein, a fusion protein according to any one of claims 10 to 13, a single guide RNA (sgRNA) and a helper single guide RNA (hsgRNA), wherein the sgRNA and the hsgRNA are capable of hybridizing to the target nucleic acid, wherein the cytosine is located between the 4th and 8th nucleotides at the 3' end of a protospacer adjacent motif (PAM) sequence on the target nucleic acid sequence, and wherein the catalytic domain comprises the amino acid sequence of SEQ ID NO:
5.
21. A base editing system, comprising: (a) a first fusion protein comprising a nucleobase deaminase, a nucleobase deaminase inhibitor, and a first RNA recognition peptide, wherein the nucleobase deaminase and the nucleobase deaminase inhibitor are separated by a protease cleavage site, and the protease cleavage site is capable of being cleaved by a protease; (b) a second fusion protein comprising an inactive portion of the protease fused to a second RNA recognition peptide different from the first RNA recognition peptide; (c) a second portion of the protease, which, in combination with the first portion, is capable of achieving the activity of the protease to cleave the protease cleavage site; (d) an auxiliary sgRNA, wherein the auxiliary sgRNA further comprises a first RNA recognition site that can be recognized by the first RNA recognition peptide; (e) an sgRNA, the sgRNA further comprising a second RNA recognition site that can be recognized by the second RNA recognition peptide; and (f) Cas protein, Wherein the nucleobase deaminase is a protein according to any one of claims 1 to 9.
22. The base editing system of claim 21, wherein the first fusion protein further comprises a uracil glycosylase inhibitor (UGI).
23. The base editing system of claim 21 or 22, wherein the Cas protein further comprises one, two or three UGIs, wherein the UGIs are capable of being cut from the Cas protein.
24. A polynucleotide comprising a first segment encoding (a) a first fusion protein comprising a nucleobase deaminase, a nucleobase deaminase inhibitor, and a first RNA recognition peptide, wherein the nucleobase deaminase and the nucleobase deaminase inhibitor are separated by a protease cleavage site, the protease cleavage site being cleavable by a protease; a second fragment encoding (b) a second fusion protein comprising an inactive portion of the protease fused to a second RNA recognition peptide different from the first RNA recognition peptide; a third fragment, the third fragment encoding (c) a second portion of the protease, the second portion in combination with the first portion being capable of achieving the protease activity to cleave the protease cleavage site; a fourth segment, the fourth segment encoding (d) an auxiliary sgRNA, the auxiliary sgRNA further comprising a first RNA recognition site that can be recognized by the first RNA recognition peptide; and a fifth segment, wherein the fifth segment encodes (e) sgRNA, wherein the sgRNA further comprises a second RNA recognition site that can be recognized by the second RNA recognition peptide, wherein the first segment, the second segment and the third segment are configured to be transcribed into a single mRNA molecule, wherein (1) the first fragment and the second fragment are separated by a first separation sequence encoding a first internal ribosome entry site (IRES), and the second fragment and the third fragment are separated by a second separation sequence encoding a first self-cleaving peptide; or (2) the first fragment and the second fragment are separated by a first separation sequence encoding a second self-cleaving peptide, and The second and third fragments are separated by a second separating sequence encoding a second internal ribosome entry site (IRES).
25. The polynucleotide of claim 24, wherein the nucleobase deaminase is a protein according to any one of claims 1 to 9.
